Dostinex contains cabergoline and is used for adults with hyperprolactinemia. It lowers excess prolactin released by the pituitary gland and helps control hormone excess.
Cabergoline, the active ingredient of Dostinex, is supplied as tablets for adults with hyperprolactinemia. How much to use and how often depends on the purpose of treatment and is agreed with a doctor or pharmacist. It lowers excess prolactin released by the pituitary gland and can reduce galactorrhea, restore menstrual cycles, and support fertility. In people with prolactin-secreting pituitary tumours, it is used to control hormone excess.
Dostinex treatment is individualized according to the cause of hyperprolactinemia, prolactin blood results, symptoms, and tolerability. How much to use and how often depends on the purpose of treatment and is agreed with a doctor or pharmacist. [2]
Typical administration principles include:
A clinician may reduce the dose after prolactin has normalized and remained stable. Some people need longer-term therapy, while others can attempt a supervised withdrawal after sustained control. The Pituitary Society’s 2023 consensus statement supports regular review of prolactin levels, symptoms, and tumour status when relevant. [3]
Dostinex is supplied as tablets containing cabergoline. How much to use and how often depends on the purpose of treatment and is agreed with a doctor or pharmacist.
Cabergoline tablets are immediate-release tablets. They do not work like a daily hormonal supplement: each scheduled dose has a prolonged effect on pituitary prolactin secretion.
A split tablet may be used only when the prescribed dose requires it. The tablet should be divided cleanly along its score line, rather than broken into uneven fragments.
Dostinex contains cabergoline, a potent dopamine agonist. Dopamine is the brain’s natural brake on prolactin release. Cabergoline activates D2 dopamine receptors on lactotroph cells in the anterior pituitary, telling those cells to produce less prolactin.
A lower prolactin level may improve symptoms within weeks, while hormone stabilization and tumour assessment take longer. Blood tests and, for selected patients, pituitary imaging guide treatment decisions.
Dostinex is used when the body produces too much prolactin, a hormone made in the anterior pituitary gland. Raised prolactin can result from a prolactinoma, a benign pituitary tumour, or from other endocrine and medication-related causes. Cabergoline suppresses prolactin production and is a standard first-line treatment for many people with prolactinomas. [1] Prolactin testing helps confirm the diagnosis and track treatment response. Imaging may be needed when symptoms suggest a larger tumour.
For women, high prolactin may interfere with ovulation and cause irregular periods, amenorrhea, infertility, or milk discharge unrelated to breastfeeding. In men, it may lower testosterone, libido, fertility, and energy. The clinical aim is not only to improve a laboratory result; it is to relieve hormone-related symptoms and, where relevant, reduce tumour activity.
Hyperprolactinemia affects the reproductive hormone system. Excess prolactin can suppress gonadotropin-releasing hormone, which then reduces the signals needed for normal ovarian or testicular hormone production.
Symptoms can include:
Several avoidable errors can make Dostinex harder to tolerate or less useful.
One small but practical detail: record the dose days in a calendar rather than relying on memory. A twice-weekly medicine is easy to miss because it does not become part of a daily habit.
Dostinex is not for you if you have a known allergy to cabergoline, other ergot-derived medicines, or any tablet component. It is also unsuitable for people with a history of pulmonary, pericardial, or retroperitoneal fibrotic disorders, or evidence of heart-valve disease.
Pregnancy requires individualized endocrine care. Cabergoline can restore ovulation, so treatment plans should account for reproductive intentions early rather than after a missed period.
The most reported adverse effects of cabergoline are nausea, headache, dizziness, fatigue, constipation, abdominal discomfort, and low blood pressure on standing. In clinical studies of hyperprolactinemia, nausea and headache were among the most frequent complaints. [2]
Most people who develop nausea notice it near the start of treatment or after a dose increase. Taking the tablet with food can help. Fatigue may be mild, though it can interfere with driving or work requiring sustained attention in some people.
Rare but serious reactions need prompt medical attention. These include fainting, shortness of breath, persistent cough, chest discomfort, swelling of the legs, severe new headache, visual changes, hallucinations, or sudden compulsive behaviours such as uncontrolled gambling, spending, or sexual urges. Long-term and higher-dose dopamine agonist exposure has also been linked with fibrotic changes and heart-valve problems in some settings.
Cabergoline and bromocriptine both lower prolactin by stimulating dopamine receptors. Their practical differences matter because nausea, dizziness, and the number of weekly doses can affect adherence.
| Feature | Cabergoline in Dostinex | Bromocriptine |
|---|---|---|
| Usual dosing pattern | Once or twice weekly | Usually daily |
| Duration of action | Long acting | Shorter acting |
| Tolerability pattern | Often better gastrointestinal tolerability | Nausea and dizziness may be more limiting |
Cabergoline is often preferred when a less frequent schedule is useful or when bromocriptine has caused troublesome gastrointestinal effects. Bromocriptine remains an established dopamine agonist and may be selected in specific reproductive or endocrine circumstances.
The advantage of Dostinex is convenience. The limitation is that its long action also means an unwanted effect may not disappear immediately after one missed dose.
In endocrine practice, doctors usually focus on two measures: symptom improvement and prolactin response. A person may feel better before the blood result has fully normalized, while another may have few symptoms despite a markedly elevated prolactin level. Both patterns need follow-up.
Doctors also look for the reason prolactin became elevated. A pituitary tumour, thyroid disorder, kidney disease, pregnancy, and certain medicines can all affect prolactin. Cabergoline treats hormone excess; it does not remove the need to assess its cause.
For prolactinomas, clinicians may use repeat MRI imaging when tumour size or visual symptoms warrant it. The World Health Organization recognizes infertility as a condition affecting people of reproductive age, and correcting hyperprolactinemia can be an important part of fertility care when excess prolactin is the cause. [4]
Dostinex 0.5 mg tablets may be split when a prescriber has ordered a 0.25 mg dose and the tablet is designed to be divided. Crushing or chewing is not usually needed and can make it harder to retain the full prescribed amount. Use a tablet cutter if a clean half-tablet is required. The 2011 FDA prescribing information for cabergoline describes gradual dosing rather than altering tablets to create unplanned doses.
Cabergoline can cause dizziness, sleepiness, fatigue, or sudden sleep episodes in some people. Avoid driving, climbing ladders, or operating machinery until you know how the medicine affects you personally. This is most relevant after treatment starts or after a dose increase. Health Canada advises caution with medicines that may impair alertness, especially during early treatment. The 2011 FDA prescribing information also describes somnolence and advises caution with activities requiring alertness.
Older adults can use cabergoline when it is clinically indicated, though clinicians often watch more closely for postural hypotension, dizziness, heart-valve concerns, and interactions with blood-pressure medicines. Standing blood pressure and symptom review can be useful when treatment begins. Age alone does not determine suitability. The 2023 Pituitary Society consensus emphasizes individual assessment of comorbidities during dopamine-agonist therapy.
Dostinex can be taken with or without food. Taking it with a meal is often more comfortable for people who develop nausea or stomach upset. Food does not replace the need to follow the assigned weekly schedule. The FDA cabergoline prescribing information, updated in 2011, permits oral administration without a mandatory fasting requirement.
Cabergoline has a long half-life, so its prolactin-lowering effect supports once- or twice-weekly dosing rather than daily use. The full clinical response depends on the prolactin level, underlying cause, and whether the dose is being adjusted. A missed dose should not be compensated for by doubling the next one. The Endocrine Society guideline published in 2011 describes cabergoline as a long-acting dopamine agonist for hyperprolactinemia.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
I used Dostinex for elevated prolactin for four months. My headaches became less frequent and my blood tests improved. I felt light-headed after the first two doses, so I started taking it with supper and getting up slowly the next morning.
My periods had been irregular for a long time before my endocrinologist found the prolactin issue. I took the prescribed half-tablet dose twice a week. By the second month, my cycle was more regular, though nausea on dose day was annoying at first.
I took it for a prolactinoma while trying to conceive. Remembering two set days each week helped me a lot. I had constipation and mild fatigue early on, but those settled after my dose stayed the same for a while.
The medicine lowered my prolactin, but I did not like the dizziness after a dose increase. My clinician adjusted the plan rather than having me push through it. That made the treatment easier to continue.
